The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

NANot yet recruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Metabolic Dysfunction Associated Fatty Liver DiseaseCompensated Liver Cirrhosis
Interventions
DRUG

Chiglitazar 64mg

Chiglitazar 64mg, oral, qd, for 72 weeks

DRUG

Placebo

Placebo, oral, qd, for 72 weeks

Trial Locations (4)

100015

Beijing Ditan Hospital, Capital Medical University, Beijing

100044

Peking University People's Hospital, Beijing

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100069

Beijing Youan Hospital, Capital Medical University, Beijing

All Listed Sponsors
collaborator

Beijing Ditan Hospital

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

Beijing YouAn Hospital

OTHER

lead

Beijing Friendship Hospital

OTHER

NCT06773221 - The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis | Biotech Hunter | Biotech Hunter